Table 1 pan-Trk immunohistochemical staining in BCOR family of tumors and controls.
From: NTRK3 overexpression in undifferentiated sarcomas with YWHAE and BCOR genetic alterations
Positive cases | Intensity | Extent (%) | |||
|---|---|---|---|---|---|
Strong | Moderate | Weak | |||
BCOR family sarcoma | |||||
YWHAE-rearranged soft tissue sarcoma | 3/3 (100%) | – | 3/3 (100%) | – | 90~95 |
BCOR ITD sarcoma of soft tissue | 4/5 (80%) | – | 2/5 (40%) | 2/5 (40%) | 30~90 |
Clear cell sarcoma of kidney | 6/8 (75%) | 1/8 (13%) | 2/8 (25%) | 3/8 (38%) | 10~90 |
BCOR-CCNB3 sarcoma | 8/12 (67%) | 1/12 (8%) | 4/12 (33%) | 3/12 (25%) | 10~95 |
KMT2D-BCOR sarcoma | 2/2 (100%) | 1/2 (50%) | 1/2 (50%) | – | 60~95 |
BCOR-CHD9 sarcoma | 1/1 (100%) | 1/1 (100%) | – | – | 100 |
Round cell sarcoma with ZC3H7B-BCOR | 0/1 | – | – | – | – |
OFMT with ZC3H7B-BCOR | 3/3 (100%) | – | 3/3 (100%) | – | 80~90 |
Control group | |||||
Other soft tissue tumors known to express BCOR | |||||
Solitary fibrous tumor | 15/15 (100%) | 13/15* (87%) | 2/15 (13%) | – | 35~100 |
Synovial sarcoma (whole section) | 2/7 (29%) | – | 2/7 (29%) | – | 20~90 |
Synovial sarcoma (TMA) | 1/50 (2%) | – | 1/50 (2%) | – | 90 |
Other round cell sarcomas | |||||
Ewing sarcoma | 2/6 (33%) | 1/6# (17%) | – | 1/6 (17%) | 10~85 |
CIC-DUX4 sarcoma | 0/4 | – | – | – | – |
Other sarcomas | |||||
Chondrosarcoma (TMA) | 0/20 | – | – | – | – |
Chordoma (TMA) | 0/20 | – | – | – | – |
Myxofibrosarcoma (TMA) | 0/20 | – | – | – | – |
Angiosarcoma (TMA) | 0/40 | – | – | – | – |
MPNST (TMA) | 0/20 | – | – | – | – |
Myxoid liposarcoma (TMA) | 0/20 | – | – | – | – |
Low-grade fibromyxoid sarcoma (TMA) | 1/10 (10%) | – | – | 1/10 (10%) | 90 |
